Attorney's Docket No.: 3800024.00324 / 1112US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Zhi et al. Art Unit: 1621

Serial No.: 10/590,119 Examiner: Katakam, Sudhakar

Filed : June 11, 2007 Conf. No. : 1033 Cust. No. : 77202

Title : ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND

METHODS

Mail Stop: Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN ACCORD WITH 37 C.F.R. §§ 1.97-1.98

Because this Supplemental Information Disclosure Statement is filed before the receipt of a First Office Action on the Merits for the above-captioned application, a fee is not required. If it is determined that a fee for filing these papers is required, the Commissioner is authorized to charge Deposit Account No. 02-1818.

In accord with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all information known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Supplemental Information Disclosure Statement that is prepared in accord with the requirements of 37 C.F.R. §§1.97-1.98. Form PTO-1449 (1 page) and copies of the cited non U.S. Patent documents are provided herewith.

The documents cited on the Form PTO-1449 are in the English language. Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

Applicant also makes known to the Examiner the following U.S. Patent Applications that are commonly owned and/or has one or more inventors in common with the instant application:

CERTIFICATE OF MAILING BY "EXPRESS MAIL" "Express Mail" Mailing Label Number EM 315456038 US Date of Deposit: January 29, 2010

I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1459 Alexandria, VA, 223 15 1450.

Myanie

Stefanie Dost

Attorney's Docket No.: 3800024.00324/1112US Supplemental Information Disclosure Statement

Serial No.: 10/590,119 Filed: June 11, 2007

Applicant: Zhi et al.

Application No.	Filing Date	Attorney Docket No.
US 11/883,247	07/26/07	3800024.00451/1119US
US 12/084,797	02/20/09	3800024.00493/1123US
US 11/921,366	02/27/09	3800024.00461/1124US
US 11/931,395	10/31/07	3800024.00543/4204B

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all information known by Applicant or Applicant's representative that may be material to the examination of the subject application, this Supplemental Information Disclosure Statement (sIDS) includes a subsequent publication by inventors of this application.

The table below includes a column that provides a space for the Examiner's initials next to the document to be considered. The document cited on the table below is in the English language. Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed item is necessary. This Supplemental Information Disclosure Statement includes the application number of the application in which the IDS is being submitted, a column that provides a blank space next to the citation for the Examiner's initials, a heading on the listing that clearly indicates the list is an Information Disclosure Statement, and a copy of the document listed below. Therefore, this sIDS is in compliance with 37 CFR §§ 1.97, 1.98 and MPEP § 609 and Applicant respectfully requests that Examiner consider and initial all information listed in the table below.

Examiner Initial	Document	
	Higuchi et al., "Potent, nonsteroidal selective androgen receptor modulators (SARMs) based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones," Bioorg. Med. Chem. Lett. 17:5442-5446 (2007).	

Although these documents and information are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the documents or information, singly or in any combination thereof, is effective as prior art against the subject application. In accord with 37 C.F.R. §1.97(g and h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

Applicant: Zhi et al. Serial No.: 10/590,119 Filed: June 11, 2007 Attorney's Docket No.: 3800024.00324/1112US Supplemental Information Disclosure Statement

Applicant respectfully requests that the Examiner review the foregoing information and that it be made of record in the file history of the above-captioned application.

Respectfully submitted

Stephanie Seidman Reg. No. 33,779

Attorney Docket No. 3800024.00324/1112US
Address all correspondence to: 77202
Stephanie Seidman
K&L Gates LLP
3580 Carmel Mountain Road, Suite 200
San Diego, California 92130
Telephana (252) 500 7410

Telephone: (858) 509-7410 Facsimile: (858) 509-7460

email: stephanie.seidman@klgates.com